Safety of Estrogens in Lupus: Hormone Replacement Therapy
Terminated · Phase 3 · NCT00000419
Conditions: Systemic Lupus Erythematosus
At a glance
- Research payments reported, 2025
- $2,541
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 350
About the trial
- Sponsor
- NYU Langone Health (with National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Office of Research on Women's Health (ORWH))
- Tested
- Premarin and Provera (drug)
- Dates
- Started 1996-04; completion 2002-08
- Results posted
- Not yet
Safety of Estrogens in Lupus Erythematosus - National Assessment (SELENA) is a study to test whether postmenopausal women with systemic lupus erythematosus (SLE, or lupus) can safely use the hormone estrogen. In this part of the study, we will look at the effects of estrogen replacement therapy on the activity and severity of disease in women with SLE.
From ClinicalTrials.gov, last updated 2013-05-03. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Chiesi USA, Inc. reported $2,541 in research payments for this study in 2025 (7 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Crn Clinical Research Network LLC $2,541
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.